Gavi approves malaria vax funding for sub-Saharan Africa

The Board of Gavi, the Vaccine Alliance has approved a number of measures aimed at tackling malaria, driving equitable global access to COVID-19 vaccines and maintaining, restoring and strengthening routine immunisation in 2022. The Board approved a new malaria vaccination programme to support the introduction, procurement and delivery of the malaria vaccine to Gavi-eligible countries in sub-Saharan Africa. An initial investment of $ 155.7 million for 20222025 will initiate the implementation of this additional tool in the fight against malaria alongside currently recommended malaria control interventions, which could save tens of thousands of lives annually and drive down child mortality in Africa. The Board has also approved the Vaccine Alliance’s strategic direction and role in COVAX. In 2022, Gavi, through COVAX, will continue building the foundations of COVID-19 protection with a focus on lower-income countries and the most in need; deploying a flexible portfolio of COVID-19 vaccines to manage uncertainty and anticipate risk; and providing support for delivery at-scale.